PEGylated apoptotic Protein-Loaded PLGA microspheres for cancer therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 739-748

  Byeon, Hyeong Jun ^a   Kim, Insoo ^a   Choi, Ji Su ^a   Lee, Eun Seong ^b   Shin, Beom Soo ^c   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Catholic University of Daegu   (South Korea)

Author keywords

Controlled release; Pancreatic cancer; PEGylation; Poly(D,L lactic co glycolic acid); TRAIL

Indexed keywords

MACROGOL; MICROSPHERE; POLYGLACTIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; LACTIC ACID; MACROGOL DERIVATIVE; PEGYLATED TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DOMAIN; SCANNING ELECTRON MICROSCOPY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY;

AGOUTI PACA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSPHERES; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RECOMBINANT FUSION PROTEINS;

EID: 84921801447     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S75821     Document Type: Article

References (29)

1. Taluja A, Youn YS, Bae YH. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. J Mater Chem. 2007;17:4002-4014.
2. Gupta RK, Singh M, O'Hagan DT. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev. 1998;32(3):225-246.
3. Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2000;17(10):1159-1167.
4. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364(2):298-327.
5. Pai SS, Tilton RD, Przybycien TM. Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J. 2009;11(1):88-98.
6. Fu K, Klibanov AM, Langer R. Protein stability in controlled-release systems. Nat Biotechnol. 2000;18(1):24-25.
7. Diwan M, Park TG. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Control Release. 2001;73(2-3):233-244.
8. Diwan M, Park TG. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int J Pharm. 2003;252(1-2):111-122.
9. Hinds KD, Campbell KM, Holland KM, Lewis DH, Piché CA, Schmidt PG. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J Control Release. 2005;104(3):447-460.
10. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10(5):559-563.
11. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66-75.
12. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med. 1999;5(2):146-147.
13. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104(2):155-162.
14. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery. 2002;132(2):127-134.
15. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163(1):71-81.
16. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004;64(19):6858-6862.
17. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun. 1999;265(2):479-483.
18. Kim TH, Youn YS, Jiang HH, Lee S, Chen X, Lee KC. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjug Chem. 2011;22(8):1631-1637.
19. Chae SY, Kim TH, Park K, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2010;9(6):1719-1729.
20. Youn YS, Na DH, Yoo SD, Song SC, Lee KC. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int J Biochem Cell Biol. 2005;37(7):1525-1533.
21. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40(7):539-551.
22. Jiang HH, Kim TH, Lee S, Chen X, Youn YS, Lee KC. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials. 2011;32(33):8529-8537.
23. Kim TH, Jiang HH, Park CW, et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release. 2011;150(1):63-69.
24. Lim SM, Kim TH, Jiang HH, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials. 2011;32(13):3538-3546.
25. Bae S, Ma K, Kim TH, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials. 2012;33(5):1536-1546.
26. Youn YS, Shin MJ, Chae SY, Jin CH, Kim TH, Lee KC. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett. 2007;29(5):713-721.
27. Byeon HJ, Choi SH, Choi JS, et al. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomater. 2014;10:142-150.
28. Yan BM, Van Dam J. Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. Can J Gastroenterol. 2008;22(4):405-410.
29. Verna EC, Dhar V. Endoscopic ultrasound-guided fine needle injection for cancer therapy: the evolving role of therapeutic endoscopic ultrasound. Therap Adv Gastroenterol. 2008;1(2):103-109.